Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prestige floats $100 mil. note for Blacksmith buy

This article was originally published in The Tan Sheet

Executive Summary

Prestige Brands sells $100 million worth of debt to help finance its acquisition of Blacksmith Brands. The senior notes the firm announced Oct. 22 will have the same terms as the 8.25 percent notes the company issued in March and are due in 2018. Prestige Sept. 20 announced its $190 million acquisition of year-old Blacksmith, which markets brands including denture products Efferdent and Effergrip, cough and cold products PediaCare and Luden's and allergy drug NasalCrom (1"The Tan Sheet" Sept. 27, 2010)

You may also be interested in...

Prestige Brands Makes "Seismic Shift" To OTC With Blacksmith Acquisition

On the eve of Blacksmith Brands' one-year anniversary, co-founder and CEO Peter Mann fulfills his promise to cash in on the startup in a $190 million sale to Prestige Brands Holdings, which Mann also helped launch

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts